Novus Advisors’s AbbVie ABBV Stock Holding History

Novus Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,482	Closed	-$310K	–	77
2025 Q1	$310K	Sell	1,482 -138	-9%	-$26.8K	0.31%	82
2024 Q4	$288K	Buy	+1,620	New	+$298K	0.29%	81

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Novus Advisors's ABBV Position: Q2 2025 in Review

Novus Advisors sold out of AbbVie (ABBV) in Q2 2025, closing a stake of 1,482 shares — an estimated $310K sold.

Novus Advisors first reported a position in ABBV in Q4 2024 and held it in 2 quarters. The position peaked at $310K in Q1 2025. 3,781 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

Novus Advisors reported no remaining AbbVie position as of Q2 2025 after selling out during the quarter.
Novus Advisors sold 1,482 AbbVie shares in Q2 2025, an estimated $310K.
Novus Advisors first reported a position in AbbVie in Q4 2024 and held it in 2 quarters.
Novus Advisors's AbbVie position peaked at $310K in Q1 2025.
3,781 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on Novus Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.